Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease

Table 2 Associated comorbidities in the enrolled participants

Comorbid condition	Frequency	Percentage
Diabetes mellitus	169	16.54
Hypertension	152	14.87
Dyslipidemia	16	1.57
Chronic obstructive pulmonary disease	10	0.98
Hypothyroidism	9	0.88
Arthritis	8	0.78
Asthma	8	0.78
Obesity	6	0.59
Migraine	3	0.29
Osteoarthritis	3	0.29
Allergic asthma	2	0.20
COPS	2	0.20
Hyperlipidemia	2	0.20
Pulmonary tuberculosis	2	0.20
Rheumatoid arthritis	2	0.20
Systemic hypertension	2	0.20
Chronic pancreatitis	1	0.10
Common bile duct stone	1	0.10
Cholelithiasis	1	0.10
Chronic kidney disease	1	0.10
Chronic liver disease	1	0.10
Renal calculi	1	0.10
Lumbar spondylitis	1	0.10
Cardiovascular diseases	1	0.10
Grade II fatty liver	1	0.10
Uterine fibroid	1	0.10